Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
(Reuters) -Immunovant said on Wednesday its drug for a type of chronic autoimmune disease affecting muscles met the main goal of improving some patients' ability to perform daily activities in a ...
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...
The pressure in the spinal canal and brain can then be measured. A small amount of CSF is removed and sent for testing to find out if there is high protein, an infection, or other problems.
The aim of the questionnaire was to understand how many patients with CIDP who did not respond to IVIG therapy the healthcare professionals followed, how many of these patients had had genetic testing ...
Update, March 1, 2025 (08:45 PM ET): The new Multi Shortcuts button we spotted Google preparing for last month now appears to be in active testing. While it’s not yet available on all devices ...
Thanks for the question about CIDP launch. As I shared ... the DOK7 mutation in human beings and that's exactly what we're testing for CMS. Think of a genetic form of MG which has overlapped ...
“We are extremely proud of the initial launch efforts of VYVGART Hytrulo in CIDP, where the strength of our data has driven early positive feedback from both patients and physicians. This execution ...
If you’re sexually active, regular testing for sexually transmitted diseases (STDs) and infections (STIs) is crucial to protect your health and the health of your partners. While you can get ...
One type, the immune-mediated demyelinating neuropathies, includes Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and ...
POWL's stock is speculative due to uncertainties in capturing data center capex and potential market glut post-2029, despite promising short-term revenue. The stock's intrinsic value is estimated ...